1. Schering Aktiengesellschaft (21 from 1,384 patents)

2. Bayer Pharma Aktiengesellschaft (15 from 378 patents)

3. Bayer Schering Pharma Ag (10 from 192 patents)

4. Astrazeneca Ab (9 from 1,500 patents)

5. Bayer Intellectual Property Gmbh (7 from 721 patents)

6. Bayer Pharma Aktiengesselschaft (1 from 1 patent)

7. Schering Aktiengsellschaft (1 from 1 patent)

8. Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts (160 patents)

1. 10919862 - Fused imidazoles as mIDH1 inhibitors

2. 10442772 - Benzimidazol-2-amines as mIDH1 inhibitors

3. 10137110 - 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors

4. 10138226 - Benzimidazol-2-amines as MIDH1 inhibitors

5. RE47047 - 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents

6. 9957235 - Benzimidazol-2-amines as mIDH1 inhibitors

7. 9951027 - Benzimidazol-2-amines as MIDH1 inhibitors

8. 9738632 - Phenyl and benzodioxinyl substituted indazoles derivatives

9. 9604989 - Imidazopyridazines as Akt kinase inhibitors

10. 9512110 - Phenyl and benzodioxinyl substituted indazoles derivatives

11. 9370517 - Substituted pyrazolopyrimidines as Akt kinase inhibitors

12. 9260435 - Substituted imidazopyrazines as Akt kinase inhibitors

13. 9206185 - Imidazopyridazines as Akt kinase inhibitors

14. 8987273 - Substituted imidazo[1,2-B]pyridazines

15. 8987286 - Substituted pyrimido[1,2-b]indazoles and their use as modulators of the Pi3K/Akt pathway